How much weight comes back after stopping a GLP-1 medication?

On average about two-thirds within a year under trial conditions. STEP 1 participants regained roughly two-thirds of their loss one year after stopping (net loss fell from 17.3% to 5.6%, Wilding 2022, PMID 35441470), and a meta-regression of 6 RCTs estimates about 60% regain after one year, with a long-term plateau near 75% (Budini 2026, PMID 41938838).

Is the rebound caused by a lack of discipline?

No, it reflects biology. After weight loss, appetite hormones remain in a hunger-promoting state for at least a year (Sumithran 2011, PMID 22029981), and resting energy expenditure stays suppressed for years (Fothergill 2016, PMID 27136388). Once the medication is removed, these defense mechanisms resurface.

Does staying on the medication actually prevent the rebound?

In controlled trials, yes. In SURMOUNT-4, the group that continued tirzepatide lost an additional 5.5%, while the placebo group regained 14.0%. 89.5% vs. 16.6% kept at least 80% of their loss (Aronne 2024, PMID 38078870). This is one reason obesity is classified as a chronic condition requiring ongoing treatment.

Does only the weight come back, or the metabolic markers too?

Both. A meta-analysis of 18 RCTs found rebound in both weight and HbA1c after discontinuation (obesity: +5.63 kg, HbA1c +0.25%; type 2 diabetes: +2.03 kg, HbA1c +0.65%, Tzang 2025, PMID 41399474).

Is a treatment period pointless if most of the weight comes back?

No. The rebound plateaus below baseline weight: models estimate that about a quarter of the weight lost remains off long term (Budini 2026, PMID 41938838), and real-world averages can differ from the trial figures because many people restart or add extra support. That said, sustained loss is generally tied to sustained treatment.

Where do research peptides like retatrutide and cagrilintide fit in?

Compounds such as retatrutide (a triple GIP/GLP-1/glucagon receptor agonist) and cagrilintide (a long-acting amylin analog often studied alongside semaglutide) are among the molecules researchers are studying in the context of the magnitude and maintenance of weight loss. These are research peptides for laboratory use, not the approved branded medications from the clinical trials cited above, and nothing here is a recommendation for use, dosing, or therapy.

Weight Regain After Stopping GLP-1: What the Rebound Research Shows

TL;DR: What the rebound studies show

STEP 1: One year after stopping semaglutide, about two-thirds of the lost weight had returned (net -5.6% instead of -17.3%).
SURMOUNT-4: Participants who continued tirzepatide lost additional weight. Those switched to placebo regained 14.0 percentage points.
2026 meta-regression (6 RCTs): The model estimates the rebound plateaus at around 75% of the weight lost, meaning roughly a quarter stays off long term.
Mechanism: Appetite hormones and resting energy expenditure stay shifted toward regain for months to years after weight loss. That is biology, not a lack of discipline.
Real-world data: Average figures outside controlled trials often come out smaller, because many people restart the medication or switch to a different one.

Semaglutide and tirzepatide are among the most extensively studied compounds of recent years when it comes to weight reduction. A less prominent but equally well-documented question is what happens once treatment ends. This article summarizes the published evidence on weight rebound, with study figures, mechanism, and the limits of the current data.

How much weight comes back?

The clearest answer comes from the extension phase of the STEP 1 trial. In the original study, 1,961 adults with obesity and no diabetes achieved a mean weight reduction of 17.3% after 68 weeks of semaglutide 2.4 mg. One year after stopping both the medication and the lifestyle intervention, weight regain reached 11.6 percentage points, leaving a net loss of only 5.6% relative to baseline. That corresponds to roughly two-thirds of the originally lost weight.

Methodology: STEP 1 Extension

Study: Wilding JPH et al., Diabetes Obes Metab 2022;24(8):1553-1564. PMID 35441470. Design: 68 weeks of semaglutide 2.4 mg plus lifestyle intervention, followed by complete discontinuation of both medication and intervention, with 1 year of follow-up. Endpoint: Percent weight change from baseline. Authors' conclusion: Continued treatment is necessary to maintain the effect.

SURMOUNT-4 shows a similar pattern for tirzepatide. After a 36-week open-label lead-in phase at the maximum tolerated dose (10 or 15 mg), the mean weight reduction was 20.9%. In the subsequent 52-week double-blind phase, participants switched to placebo regained 14.0 percentage points. Those who continued tirzepatide lost an additional 5.5 percentage points. Over the full 88 weeks, the continued-treatment group stood at -25.3%, versus -9.9% for the placebo group. 89.5% of participants on continued treatment maintained at least 80% of the weight they had lost during the lead-in phase, compared with only 16.6% on placebo.

Methodology: SURMOUNT-4

Study: Aronne LJ et al., JAMA 2024;331(1):38-48. PMID 38078870 (published online December 11, 2023). Design: 36-week open-label lead-in with tirzepatide (max tolerated dose), followed by randomization to 52 weeks double-blind continued tirzepatide vs. placebo. Endpoint: Percent weight change over the full 88 weeks.

A meta-regression published in 2026 confirms the pattern across multiple studies. It pooled 6 randomized controlled trials with 3,236 participants and modeled the weight trajectory after discontinuation using an exponential recovery model. About 60% of the weight lost during treatment had returned one year after stopping. The model estimates a plateau at 75.3% of the weight lost (95% CI 68.9-81.6), with a half-life of roughly 23 weeks. On average, about a quarter of the loss remains long term, while three-quarters returns.

Methodology: 2026 meta-regression

Study: Budini B et al., eClinicalMedicine 2026. PMID 41938838. DOI 10.1016/j.eclinm.2026.103796. Design: Pooled analysis of 6 RCTs (n=3,236) using an exponential recovery model to map the weight trajectory after discontinuation. Endpoint: Modeled plateau of weight rebound as a share of the original loss.

Not just the scale: metabolic markers rebound too

The rebound is not limited to body weight. A meta-analysis of 18 RCTs with 3,771 participants found that after stopping a GLP-1 receptor agonist, people with obesity gained on average 5.63 kg (95% CI 3.52-7.73) and HbA1c rose by 0.25% (0.18-0.32). In type 2 diabetes, weight gain was 2.03 kg (1.63-2.42) and HbA1c rose by 0.65% (0.22-1.08).

Methodology: Metabolic rebound

Study: Tzang CC et al., "Metabolic rebound after GLP-1 receptor agonist discontinuation," eClinicalMedicine 2025. PMID 41399474. DOI 10.1016/j.eclinm.2025.103680. Design: Meta-analysis of 18 RCTs (n=3,771), analyzed separately for obesity and type 2 diabetes cohorts. Endpoint: Change in body weight and HbA1c after discontinuation.

Why this happens: the body defends its old weight

Two older but foundational mechanism studies explain why rebound occurs so reliably. Weight loss triggers a coordinated homeostatic defense of the previous body weight set point: appetite-regulating hormones shift toward hunger and stay shifted for at least a year, while resting energy expenditure drops more than body size alone would explain, remaining suppressed for years. GLP-1 receptor agonists work by counteracting these appetite signals from the outside. Once the medication is removed, the underlying biology resurfaces and drives the rebound. This is physiology, not a failure of willpower.

In a controlled diet-induced weight-loss study, the hormonal drivers of rebound (lower leptin, higher ghrelin, altered PYY/GLP-1/amylin, and others) were still present 62 weeks after weight loss and had not returned to pre-loss levels.

Methodology: Hormonal adaptation

Study: Sumithran P et al., N Engl J Med 2011;365(17):1597-1604. PMID 22029981. DOI 10.1056/NEJMoa1105816. Design: Controlled diet-induced weight-loss study measuring appetite-regulating hormones up to 62 weeks after weight loss.

Six years after massive weight loss, participants in the "Biggest Loser" cohort who had regained most of their weight showed resting energy expenditure roughly 704 kcal/day below baseline, along with a persistent metabolic adaptation of about -499 kcal/day. At the reduced weight, the body permanently burns fewer calories, which further amplifies the drive to eat.

Methodology: Metabolic adaptation

Study: Fothergill E et al., Obesity (Silver Spring) 2016;24(8):1612-1619. PMID 27136388. DOI 10.1002/oby.21538. Design: Six-year follow-up of "Biggest Loser" participants after initial major weight loss, measuring resting energy expenditure.

The limits of this data

Important: what these numbers do not show

The figures from STEP 1 and SURMOUNT-4 come from designs with complete discontinuation and no replacement treatment. They represent a "worst-case" scenario. Real-world averages are less clean because of restarts and switches between medications.
The 75.3% plateau from the meta-regression is a modeled estimate from only 6 RCTs with limited follow-up beyond about one year. The long-term plateau is an extrapolation, not a direct observation over many years.
The two mechanism studies (Sumithran, Fothergill) examined diet-induced weight loss, not GLP-1 medications. They explain the biology of the set-point mechanism but do not directly demonstrate the exact mechanism after GLP-1 discontinuation.
Real-world persistence figures vary widely by database, payer, country, and year, and are driven mainly by cost and access rather than clinical response. They do not translate directly to a research context or a non-US setting.
Individual variation is large: some people keep more of the loss, others regain nearly all of it. Averages obscure this range.

A useful counter-nuance is that the STEP 1 and SURMOUNT-4 figures describe complete discontinuation with no replacement treatment, not the full range of real-world outcomes. In practice many people restart the medication, switch to a different one, or add intensive lifestyle support, which can flatten the average regain compared to the trial pattern. Individual rebound still follows the trial pattern among those with no replacement in place.

Consistent with this, real-world treatment duration tends to be short: a real-world analysis of insurance claims data found that one-year persistence on weight-indicated GLP-1 agonists rose from 33.2% among people starting therapy in 2021, through 40.2% (2023), to 60.9% in the first half of 2024 (Marshall & Gleason et al., J Manag Care Spec Pharm 2026, PMID 41760566). The leading reasons for discontinuation are cost and insurance issues, side effects, and supply shortages, not a failure of the drug to work.

What the research suggests about maintenance

The consistent signal from the STEP 1 extension and SURMOUNT-4 is that continued treatment maintains and extends weight loss, while discontinuation leads to rebound. Whether a reduced maintenance dose or an intermittent schedule can hold weight with fewer weeks of compound exposure remains an open research question, not an established protocol. In this dataset, obesity behaves like a chronic, relapse-prone condition.

Related research connections (GIP/GLP-1/glucagon and amylin)

Beyond the approved medications, research is also looking at other molecules in the context of the magnitude and maintenance of weight loss. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors. Cagrilintide is a long-acting amylin analog frequently studied alongside semaglutide. Important for our audience: these are research peptides for laboratory use, not the approved branded medications from which the clinical trial data cited above are drawn. Nothing in this article is a recommendation for use, dosing, or therapy.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Cagrilintidemetabolic

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

For more on the clinical trial data itself, see GLP-1 trials overview, and on dosing questions in the published literature: Dosing data from research.

All products mentioned in this article are sold exclusively for laboratory and research purposes. They are not intended for human consumption or therapeutic use. The clinical trials cited (semaglutide, tirzepatide) refer to approved branded medications, not the research peptides offered by PeptidesDirect.